Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit
2011

Evaluating the Anti-Angiogenic Properties of RGDechiHCit

Sample size: 31 publication 10 minutes Evidence: moderate

Author Information

Author(s): Gaetano Santulli, Maria Felicia Basilicata, Mariarosaria De Simone, Carmine Del Giudice, Antonio Anastasio, Daniela Sorriento, Michele Saviano, Annarita Del Gatto, Bruno Trimarco, Carlo Pedone, Laura Zaccaro, Guido Iaccarino

Primary Institution: Federico II University of Naples, Italy

Hypothesis

The study aims to evaluate the effects of RGDechiHCit on angiogenesis in vitro and in vivo.

Conclusion

RGDechiHCit selectively inhibits endothelial αVβ3 integrin, which may have clinical implications for treating conditions like cancer and inflammatory diseases.

Supporting Evidence

  • RGDechiHCit inhibits cell proliferation in endothelial cells.
  • RGDechiHCit delays wound healing in animal models.
  • RGDechiHCit shows an antiangiogenic effect in Matrigel plug assays.

Takeaway

This study found that a new drug called RGDechiHCit can stop certain cells from growing and forming new blood vessels, which is important for treating diseases like cancer.

Methodology

The study used in vitro assays on endothelial and vascular smooth muscle cells, and in vivo models in rats and mice to assess the effects of RGDechiHCit.

Potential Biases

Potential bias may arise from the small sample sizes in animal studies and the lack of long-term follow-up.

Limitations

The study's findings may be limited by the short half-life of RGDechiHCit in serum, which could affect its therapeutic potential.

Participant Demographics

The study involved Wistar Kyoto rats and C57BL/6 mice, with specific weights and ages noted.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-9-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication